Complexo Hospitalario Universitario de Santiago
Centro de atención
University of Bari Aldo Moro
Bari, ItaliaPublicacións en colaboración con investigadores/as de University of Bari Aldo Moro (18)
2024
-
Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank
Clinical and experimental rheumatology, Vol. 42, Núm. 2, pp. 277-287
-
Elevated Troponins after COVID-19 Hospitalization and Long-Term COVID-19 Symptoms: Incidence, Prognosis, and Clinical Outcomes—Results from a Multi-Center International Prospective Registry (HOPE-2)
Journal of Clinical Medicine, Vol. 13, Núm. 9
-
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies
Joint Bone Spine, Vol. 91, Núm. 2
-
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
The Journal of rheumatology, Vol. 51, Núm. 4, pp. 378-389
2023
-
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
Journal of Rheumatology, Vol. 50, Núm. 8, pp. 1009-1019
-
Post-COVID-19 Symptoms and Heart Disease: Incidence, Prognostic Factors, Outcomes and Vaccination: Results from a Multi-Center International Prospective Registry (HOPE 2)
Journal of Clinical Medicine, Vol. 12, Núm. 2
2022
-
After JAK inhibitor failure: To cycle or to switch, that is the question - Data from the JAK-pot collaboration of registries
Annals of the Rheumatic Diseases, Vol. 82, Núm. 2, pp. 175-181
-
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration
Annals of the Rheumatic Diseases, Vol. 81, Núm. 10, pp. 1358-1366
-
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response
Rheumatology (Oxford, England), Vol. 61, Núm. 9, pp. 3799-3807
-
Mapping genomic loci implicates genes and synaptic biology in schizophrenia
Nature, Vol. 604, Núm. 7906, pp. 502-508
-
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
Arthritis Care and Research, Vol. 74, Núm. 7, pp. 1205-1218
-
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis
Rheumatology (Oxford, England), Vol. 61, Núm. 12, pp. 4741-4751
2021
-
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
Annals of the Rheumatic Diseases, Vol. 80, Núm. 11, pp. 1410-1418
-
In Vivo Induction of P-Glycoprotein Function can be Measured with [18F]MC225 and PET
Molecular Pharmaceutics, Vol. 18, Núm. 8, pp. 3073-3085
2020
-
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration
RMD open, Vol. 6, Núm. 3
-
Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis
Rheumatology (United Kingdom), Vol. 59, Núm. 9, pp. 2455-2461
2019
2013
-
Allergic contact dermatitis
Review of Allergy and Clinical Immunology, Vol. 23, Núm. 3-4, pp. 75-86